Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of investigational RSV maternal vaccine alone or with Boostrix in healthy non-pregnant women
2019-002258-22Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2019
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of GSK3003899A in respiratory syncytial virus disease (RSV) (3 arms), sponsored by GSK. Primary endpoint: Percentage of subjects with at least one solicited local adverse event after the first vaccination. Started Sep 2019; status: completed.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2019-002258-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002258-22.